

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/209402 A3

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)
C07K 14/54 (2006.01)

(21) International Application Number:

PCT/EP2021/059473

(22) International Filing Date:

13 April 2021 (13.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20169510.3 15 April 2020 (15.04.2020) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **CODARRI DEAK, Laura**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FREIMOSER-GRUNDSCHOBBER, Anne**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **KLEIN, Christian**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **LAUENER, Laura**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **MOESSNER, Ekkehard**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **UMAÑA, Pablo**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **SCHULENBURG, Cindy**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **VARYPATAKI, Eleni Maria**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **KASCHAU, Nikolai**; F. HOFFMANN-LA ROCHE AG, Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

02 December 2021 (02.12.2021)

(54) Title: IMMUNOCONJUGATES

(57) Abstract: The present invention generally relates to mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.



WO 2021/209402 A3